Jubak Picks
April 30, 2024 | ALV, Daily JAM, Jubak Picks, Videos |
Today’s Quick Pick is Autoliv Inc (ALV). Autoliv makes auto safety equipment from seatbelts to newer products such as driver assistance and lane keep. They have a 45% global share of the global auto safety market with growing penetration in China. (China is now about 22% of sales). With a 40% market share in China, the company has room to grow, especially as China exports more and more vehicles. As Chinese car exports grow, so too will Autoliv’s sales of safety products. Chinse cars for the domestic market include 2-3 Autoliv products. Cars for the export market include 4-5. Autoliv just announced earnings on April 25 which beat estimates by about 18% with about a 70-80% increase in earnings year over year. Morningstar calls the stock fairly valued, I think that’s an underestimate. The price to sales on the stock is currently at 0.97 and the trailing 12-month PE is 19.17, and the forward EPS is at 13. The shares also offer a 2.1% dividend yield with a buyback yield of 4.7%. Free cash flow is rising (up $170 million last year) even while the company is investing more in China, India, and Vietnam. Autoliv has also shown a solid increase in operating margin in the most recent quarter from 5.17% to 7.4% and management is hoping to drive that up to 10%. I’m adding the shares to my Jubak’s Picks Portfolio.
April 24, 2024 | Daily JAM, Dividend Income, Jubak Picks, Long Term, Stock Alerts, Top 50 Stocks, V |
Tuesday, April 23, after the market close Visa (V) reported adjusted net income of $2.51 a share. That ws 7 cent a share more than the consensus of estimates from Wall Street analysts. Earnings rose 7% year-over-year in the quarter. Revenue climbed 10% from a year prior to $8.8 billion, also exceeding Wall Street estimates
April 23, 2024 | Daily JAM, Jubak Picks, Long Term, Millennial, Stock Alerts, Volatility |
I certainly understand the sell off in shares of development stage lithium producer Lithium Americas (LAC). Today, April 23, the stock closed at $4.68 a share, down another 1.47%. On April 16 the stock closed at $6.49 after hitting $7.34 on April 11. The culprit? The company closed a previously announced stock offer to 55 million shares at a price of $5 a share to raise $275 million.
You can see the problem, right? Stock is trading at $7.34 or $6.49 and then a big public offer dumps 55 million shares on the market at $5 a share. Ouch!! So I understand the price plunge–36.2% from April 11 to the close on April 23. And as someone who owns shares in his personal portfolio, I can’t say I’m a happy camper. But I will be being more in my personal account three days after this is posted.
April 22, 2024 | Daily JAM, GLD, GOLD, Jubak Picks, Morning Briefing, NEM, Short Term |
Gold futures for June delivery closed down 2.92% on the Comex today. The metal closed at $2343.40 an ounce. The drop came on a lessening of fears that the exchange of attacks between Israel and Iran would quickly lead to a wider Middle East war. And on growing sentiment that the Federal Reserve isn’t likely to cut interest rates soon. The drop in the gold contract for June delivery was the largest since February 3, 2023 when it fell 2.8%.
April 2, 2024 | BYDDF, Daily JAM, Jubak Picks, Morning Briefing |
Today, Tesla (TSLA) reported that it delivered just 386,810 vehicles in the first three months of the year. That was the biggest difference between actual sales and Wall Street sales estimates in data going back seven years, according to Bloomberg. Most analysts expected Tesla to sell more vehicles than a year ago. Instead, deliveries ended up dropping 8.5% year-over-year. And it was the first drop in year-over-year sales since the first year of the Covid-19 pandemic.
April 1, 2024 | Daily JAM, Dividend Income, Jubak Picks, Special Reports |
Bookkeeping. I added Honeywell (HON) as Pick #6 for my New World for Dividend Investing Special Report (You can find it in the Special Report section of this site along with all the content on this market and its trends for Dividend Income investors. But I’m reposting it as a stand alone pick so no one misses it.
April 1, 2024 | Daily JAM, Jubak Picks, MRNA, Videos |
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
March 29, 2024 | Daily JAM, Dividend Income, Jubak Picks, Long Term, Special Reports, Top 50 Stocks, V |
Bookkeeping. I added Visa as Pick #5 for my New World of Dividend Investors Special Report (You can find it in the Special Report section of this site along with all the content on this market and its trends for Dividend Income investors. But I’m reposting it as a stand alone pick so no one misses it.
March 28, 2024 | AAPL, Daily JAM, Jubak Picks, Morning Briefing, Short Term, Top 50 Stocks |
Apple is likely to take its shareholders on an even wilder ride in the next six months than they’ve been on since the December all-time high at $199.62. The end result, I think is likely to be a renewed rally beginning in the fall–if you can either hold on through the volatility until then or see your way clear to timing when to buy and sell.
March 26, 2024 | Daily JAM, Jubak Picks, LLY, Mid Term, Morning Briefing, NVO, Stock Alerts, VKTX |
First, it was Viking Therapeutics (VKTX) on the attack with trial results that shows its GLP-1 dibetes/weight loss drug out performing current leader of the pack drugs fro Novo Nordisk (NVO) and Eli Lilly (LLY). On the news Viking soared.
Then Novo Nordisk struct back with data of its own showing progress on an oral formulation of its rugs. (All existing GLP-1 drugs are delivered by injection.) That cratered Viking Shares. Now, March 26, Viking has released new Phase 1 trial data from a multiple ascending dose study of the oral version of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
March 20, 2024 | Daily JAM, Jubak Picks, Mid Term, Stock Alerts |
Today’s Hot Button Moves NOW video is Buy Madrigal Pharmaceuticals (MDGL). This biotech company just received U.S. Food and Drug Administration approval for the first drug available for treating MASH (formerly known as NASH). MASH is a liver disease where fat builds up and compromise liver function. It’s measured in stages (1-4) and at stage 4, you need a liver transplant. Companies have long worked toward a treatment for the disease but have failed in trials or in getting FDA approval. The major achievements for Madrigal are efficacy in stopping the disease from progressing to the next stage and a clean label and no “black box warnings.” Additionally, this drug does not require a liver biopsy before a doctor can prescribe it and will be available after a much less invasive test. The market for this drug is forecast at $5 billion a year market. Madrigal will be able to start selling this drug in April. The Medical Technology Stock Letter, my preferred source on all things biotech, suggests buying MDGL below $300 with a target price of $400. I’m adding Madrigal Pharmaceuticals to my 12-18 month Jubak’s Picks Portfolio.
March 19, 2024 | Daily JAM, Dividend Income, EQNR, Jubak Picks, Mid Term, Special Reports, Top 50 Stocks, V |
Let’s say you’re a dividend income investor. You need cash income in retirement. Or you want your portfolio to generate cash now so you can invest in new opportunities. Or you just want the extra safety and lower risk that owning a stock with a substantial dividend can bring. Whatever your reasons–and I can think of a lot more–this is a particularly challenging financial market for dividend income investors.But I do think there are strategies dividend income investors can successfully pursue even in this challenging market. In the rest of this Special Report I’m going to explain the three ways I think you should be thinking about dividend income investing in this market. And then I’m going to give you 10 dividend stocks that I think are especially well-suited to producing income (and price appreciation, which is always nice even if you’re an income investor) in this market environment. First pick just posted–Pfizer
